FDA 483 - STgen Bio Co., Ltd. - June 25, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
STgen Bio Co., Ltd., a drug substance and drug manufacturer in Incheon, Republic of Korea, was inspected by the FDA from June 17-25, 2024. The inspection revealed significant deficiencies across multiple areas, including aseptic processing, environmental monitoring, visual inspection of sterile products, quality unit responsibilities, laboratory controls, and adherence to standard operating procedures. These issues indicate a lack of adequate controls to prevent contamination and ensure product quality and purity.
ID · 88b6c71d-4f82-4093-a06e-6f796291d3b3